Neurology

Oncology & Supportive Care

Vascular & Immunological Reaction

Gastrointestinal Disorders

Other Therapeutic Areas

Compound Name/Code ARICEPT (Liquid Formulation) UK ARICEPT (Vascular Dementia) US ARICEPT (Jelly Formulation) JP ARICEPT (Sustained Release Formulation) US, EU ARICEPT (Pediatric Usage in Chemotherapy) US ARICEPT (Pediatric Usage in Down syndrome) US ARICEPT (Lewy Body Dementia) JP E2007 (Epilepsy) US, EU, JP E2007 (Neuropathic Pain) US, EU E2007 (Migraine Prophylaxis) US E2007 (Multiple Sclerosis) EU AS-3201 (Diabetic Neuropathy) US BANZEL (Epilepsy) US ZONEGRAN (Epilepsy, Monotherapy) EU ZONEGRAN (Pediatric Indication) EU E0302 (Amyotrophic Lateral Sclerosis) JP E2014 (Cervical Dystonia) JP SEP-190 (Insomnia) JP E7389 (Breast Cancer) US, EU, JP E7389 (Non-Small Cell Lung Cancer) US E7389 (Prostate Cancer) US, EU E7389 (Sarcoma) EU E7820 (Colorectal Cancer) US E7080 (Thyroid Cancer) US MORAb-003 (Ovarian Cancer) US MORAb-009 (Pancreatic Cancer) US DACOGEN (Five-Day Dosing Regimen for MDS) US DACOGEN (Acute Myeloid Leukemia) US DACOGEN (Efficacy in Survival Benefit in MDS patients) US irofulven (Prostate Cancer) US ALOXI (Oral Formulation) US AKR-501 (Idiopathic Thrombocytopenic Purpura) US amolimogene (Cervical Dysplasia) US LUSEDRA (Sedation in Adult Patients Undergoing Diagnostic or Therapeutic Procedures) US SAFORIS (Oral Mucositis) US HUMIRA (Rheumatoid Arthritis) JP HUMIRA (Psoriasis) JP HUMIRA (Juvenile Rheumatoid Arthritis) JP HUMIRA (Ankylosing Spondylitis) JP HUMIRA (Inhibition of structural damage of joints) JP HUMIRA (Crohn's Disease) JP HUMIRA (Ulcerative Colitis) JP E5564 (Severe Sepsis) Global E5555 (Acute Coronary Syndrome) US, EU, JP E5555 (Atherothrombotic Disease) US, EU, JP E6201(Psoriasis) US T-614 (Rheumatoid Arthritis) JP ACIPHEX (Short-term Treatment of Gastro-esophageal Reflux Disease (GERD) in Adolescents) US PARIET (Non-erosive GERD) JP ACIPHEX (Long-Acting Release Formulation) US PARIET (Additional Dosage for Reflux Esophagitis) JP GASMOTIN (Gastroprokinetic Agent) Asia IOMERON (Additional Indication & formulation for Computerized Tomography) JP KES524 (Obesity Management) JP clevudine (Chronic Hepatitis B) Asia GLUFAST (Diabetes) Asia E7210 (Ultrasonic Contrast Medium) JP

Phase II

Phase III Submission Approval

1) A Phase II for epilepsy indication is ongoing in Japan. 2) A Phase II for breast cancer indication is ongoing in Japan. 3) Submission is being prepared in the U.S. 4) Application has been withdrawn temporarily. Resubmission is in preparation. 5) Approval was obtained in Thailand. Applications are under review in Malaysia, Indonesia, and the Philippines. Submission is in preparation in six other Asian countries including some ASEAN members. 6) Applications are under review in Malaysia, Thailand, Indonesia, the Philippines and India. Submission is in preparation in three other Asian countries including some ASEAN members. A Phase III study is being prepared in China. 7) Applications are under review in Malaysia, Thailand, the Philippines, Indonesia, and Singapore. Submission is in preparation in five ASEAN countries. 8) Development in Japan is being suspended. Updated: January 30, 2009

* * * * * * * * * * * * * * *1) * * * * * * * * * * * * * * * * * *2) * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *6) * * *8)

* * *

* *

*3) * * * * * * *

* * *4) *5) * * *6) *7)

* *5) *